Meridian Bioscience (VIVO) Reports Q4 EPS of $0.19, Offers FY21 Guidance

Meridian Bioscience (NASDAQ: VIVO) reported Q4 EPS of $0.19, versus $0.14 consensus. Revenue for the quarter came in at $64.2 million, versus $59.6 million consensus.

GUIDANCE:

Meridian Bioscience sees FY2021 EPS of $1.14-$1.28, versus the consensus of $1.02. Meridian Bioscience sees FY2021 revenue of $290-310 million, versus the consensus of $249.15 million.

For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.

You May Also Be Interested In

• Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance
• Wells Fargo previews Q2 midstream earnings, favors PAA and TRGP
• Levi (LEVI) Tops Q2 EPS by 4c, Offers Guidance